Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Mastocytosis 4Recurrence 2Pruritus 2Piebaldism 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Mastocytosis, Systemic 2Gastrointestinal Stromal Tumors 2Blushing 2Ovarian Neoplasms 1Metastatic Castrate Resistant Prostate Cancer 1Melanoma 1Gastro-intestinal Stromal Tumours 1Gastro-Intestinal Stromal Tumour 1Gastro Intestinal Stromal Tumor 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

Imatinib Mesylate 26Sunitinib 22nilotinib 12ripretinib 11regorafenib 7avapritinib 7tanespimycin 2pexidartinib 2masitinib 2famitinib 2Midazolam 2IDRX-42 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2umbralisib 1trastuzumab deruxtecan 1trametinib 1tinostamustine 1spartalizumab 1ribociclib 1repaglinide 1ponatinib 1perifosine 1pembrolizumab 1olverembatinib 1olaratumab 1motesanib diphosphate 1dabrafenib 1cediranib 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Stromal Tumors × masitinib × Clear all
NCT00812240 2023-02-01

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

AB Science

Phase 3 Terminated
335 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT01694277 2020-12-08

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

AB Science

Phase 3 Completed
258 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡